Pfizer Introduces Novel Myeloma Treatment in India for Patients with Limited Therapeutic Options

Pfizer Launches Elranatamab in India, Bringing New Cancer Therapy Option for Advanced Multiple Myeloma Patients

Pfizer has launched its latest cancer therapy, elranatamab, in India, providing a new treatment option for patients with advanced multiple myeloma who have exhausted existing lines of therapy. Multiple myeloma, the second most common type of blood cancer globally, remains incurable despite advances in treatment, with many patients eventually relapsing after initial therapies.

Elranatamab is a BCMA-targeted bispecific antibody designed for adults with relapsed or refractory multiple myeloma, a stage where patients typically have few remaining treatment options after undergoing at least four prior therapies. The therapy works by activating the body's immune system to attack cancer cells, binding simultaneously to CD3 on T-cells and BCMA on cancerous B-cells, effectively redirecting immune responses toward tumour destruction.

Clinical data suggests that elranatamab delivers durable responses and improved progression-free survival, offering meaningful outcomes for heavily pre-treated patients. The therapy is available as a ready-to-use subcutaneous injection, reducing time spent in hospitals compared to traditional infusion-based therapies. Patients can begin with weekly dosing, transitioning to every-other-week administration after 24 weeks if they respond well.

Read also: Lilly Launches Novel Alzheimer's Treatment Lormalzi in India at Rs 91,688 per Vial

This approach aims to reduce both patient burden and caregiver involvement, while improving adherence. For Pfizer, the launch reflects a broader strategy of bringing innovative, high-value therapies to emerging markets like India.

The Indian oncology market continues to face gaps in access to advanced therapies, particularly for patients who relapse after multiple lines of treatment. By offering an "off-the-shelf" therapy, Pfizer aims to address one of the structural limitations of more complex treatments such as CAR-T therapies, which require personalized manufacturing and longer turnaround times.

Pfizer's country president in India, Meenakshi Nevatia, stated that the introduction of elranatamab marks another step forward in bringing a highly innovative, ready-to-use targeted therapy that combines strong clinical efficacy with the convenience of every-other-week dosing. The company framed the therapy not just as a survival benefit, but as a way to improve patient quality of life — increasingly a key metric in oncology.

Read also: Eli Lilly to Launch Alzheimer's Disease Therapy Lormalzi in India This Month